Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketogenic Diet vs Orlistat in Obesity with T2DM/OSA
NCT02069197Phase 2Unknown
- Sponsor
- Mid-Atlantic Epilepsy and Sleep Center
- Start
- Jan 2014
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in obesity, type 2 diabetes mellitus (T2DM) and obstructive sleep apnea (OSA) (3 arms), sponsored by Mid-Atlantic Epilepsy and Sleep Center. Primary endpoint: Change of body mass index from baseline at 9 months. Status: unknown.
02
Conditions
obesitytype 2 diabetes mellitus (T2DM)obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02069197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069197.